PURPOSE: To test the hypothesis that reactive oxygen species contribute to the cerebral hyperperfusion in Fabry disease. MATERIAL AND METHODS: We examined the effect of intravenous injection of ascorbate on cerebral blood flow (CBF) using magnetic resonance arterial spin tagging. Nineteen patients with Fabry disease and 15 control subjects were studied as part of a randomized double-blind placebo-controlled trial of enzyme replacement therapy (ERT). RESULTS:Vertebro-basilar hyperperfusion was observed in patients with Fabry disease. A decrease in systemic ascorbate levels relative to healthy controls was found in the patients. CBF decreased after ascorbate infusion in both control subjects and patients treated with ERT. The placebo group had a significantly delayed decrease in the CBF response after ascorbate infusion. Myeloperoxidase levels were elevated in Fabry patients, consistent with ongoing inflammatory processes in these patients. CONCLUSION: Increased CBF in Fabry disease may be related to increased production of reactive oxygen species, while low plasma ascorbate levels suggests a global redox imbalance. These abnormalities were improved by ERT. These observations have implications regarding oxidative processes contributing to accelerated atherosclerosis in Fabry disease. Copyright 2004 Wiley-Liss, Inc.
RCT Entities:
PURPOSE: To test the hypothesis that reactive oxygen species contribute to the cerebral hyperperfusion in Fabry disease. MATERIAL AND METHODS: We examined the effect of intravenous injection of ascorbate on cerebral blood flow (CBF) using magnetic resonance arterial spin tagging. Nineteen patients with Fabry disease and 15 control subjects were studied as part of a randomized double-blind placebo-controlled trial of enzyme replacement therapy (ERT). RESULTS: Vertebro-basilar hyperperfusion was observed in patients with Fabry disease. A decrease in systemic ascorbate levels relative to healthy controls was found in the patients. CBF decreased after ascorbate infusion in both control subjects and patients treated with ERT. The placebo group had a significantly delayed decrease in the CBF response after ascorbate infusion. Myeloperoxidase levels were elevated in Fabry patients, consistent with ongoing inflammatory processes in these patients. CONCLUSION: Increased CBF in Fabry disease may be related to increased production of reactive oxygen species, while low plasma ascorbate levels suggests a global redox imbalance. These abnormalities were improved by ERT. These observations have implications regarding oxidative processes contributing to accelerated atherosclerosis in Fabry disease. Copyright 2004 Wiley-Liss, Inc.
Authors: C Simoncini; S Torri; V Montano; L Chico; F Gruosso; A Tuttolomondo; A Pinto; I Simonetta; V Cianci; A Salviati; V Vicenzi; G Marchi; D Girelli; D Concolino; S Sestito; M Zedde; G Siciliano; Michelangelo Mancuso Journal: J Neurol Date: 2020-07-27 Impact factor: 4.849
Authors: David F Moore; Oleg V Krokhin; Ronald C Beavis; Markus Ries; Chevalia Robinson; Ehud Goldin; Roscoe O Brady; John A Wilkins; Raphael Schiffmann Journal: Proc Natl Acad Sci U S A Date: 2007-02-14 Impact factor: 11.205
Authors: David F Moore; Monique P Gelderman; Paulo A Ferreira; Steven R Fuhrmann; Haiqing Yi; Abdel Elkahloun; Lisa M Lix; Roscoe O Brady; Raphael Schiffmann; Ehud Goldin Journal: Proc Natl Acad Sci U S A Date: 2007-04-30 Impact factor: 11.205
Authors: T Kovarnik; G S Mintz; D Karetova; J Horak; J Bultas; R Skulec; H Skalicka; M Aschermann; M Elleder; A Linhart Journal: J Inherit Metab Dis Date: 2008-11-08 Impact factor: 4.982
Authors: Jin-Song Shen; Xing-Li Meng; David F Moore; Jane M Quirk; James A Shayman; Raphael Schiffmann; Christine R Kaneski Journal: Mol Genet Metab Date: 2008-08-15 Impact factor: 4.797